Evidence of Conformational Selection Driving the Formation of Ligand Binding Sites in Protein-Protein Interfaces

PLoS Computational Biology

Volumn 10, Issue 10, 2014, Pages

  Bohnuud, Tanggis ^a   Kozakov, Dima ^b   Vajda, Sandor ^b,c  

^a BOSTON UNIVERSITY   (United States)

^b Boston University   (United States)

^c Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CONFORMATIONS; FREE ENERGY; LIGANDS; MAPPING; MOLECULES; NUCLEAR MAGNETIC RESONANCE; PEPTIDES;

BINDING-SITES; BOUND STRUCTURE; CONFORMATIONAL SELECTION; DRUG DISCOVERY; LIGAND-BINDING SITES; LIGAND-FREE; NUCLEAR MAGNETIC RESONANCE TECHNIQUES; PROTEIN-PROTEIN INTERACTIONS; PROTEIN-PROTEIN INTERFACE; SMALL MOLECULES;

BINDING SITES;

CARRIER PROTEINS AND BINDING PROTEINS; ENHANCER OF DECAPPING 3 ACTIVATOR PROTEIN; MEMBRANE ASSOCIATED GUANYLATE KINASE WITH INVERTED DOMAIN 1; PDZ PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN BCL XL; PROTEIN MDM2; UNCLASSIFIED DRUG; PROTEIN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; BINDING SITE; BOUND STATE SIMILARITY COEFFICIENT; COMPUTATIONAL SOLVENT MAPPING; CORRELATION COEFFICIENT; ENERGY METABOLISM; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR RECOGNITION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DATA BANK; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PROTEIN DATABASE;

BINDING SITES; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS;

EID: 84908351629     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003872     Document Type: Article

References (57)

1. Wells JA, McClendon CL, (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001–1009.
2. Whitty A, Kumaravel G, (2006) Between a rock and a hard place? Nature chemical biology 2: 112–118.
3. Fuller JC, Burgoyne NJ, Jackson RM, (2009) Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 14: 155–161.
4. Blundell TL, Bolanos-Garcia VM, (2009) Targeting protein interactions of p53 for therapeutic intervention: success in a frustrated landscape. Cell Cycle 8: 3631–3632.
5. Zinzalla G, Thurston DE, (2009) Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med Chem 1: 65–93.
6. Kozakov D, Hall DR, Chuang GY, Cencic R, Brenke R, et al. (2011) Structural conservation of druggable hot spots in protein-protein interfaces. Proc Nat Acad Sci U S A 108: 13528–13533.
7. Chene P, (2004) Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface. Mol Cancer Res 2: 20–28.
8. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, et al. (2007) Crystal structure of ABT-737 complexed with Bcl-x(L): implications for selectivity of antagonists of the Bcl-2 family. Cell Death and Differentiation 14: 1711–1713.
9. Wang Y, Coulombe R, Cameron DR, Thauvette L, Massariol MJ, et al. (2004) Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. J Biol Chem 279: 6976–6985.
10. Tsao DH, Sutherland AG, Jennings LD, Li Y, Rush TS, 3rdet al. (2006) Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg & Med Chem 14: 7953–7961.
11. De Luca L, Barreca ML, Ferro S, Christ F, Iraci N, et al. (2009) Pharmacophore-Based Discovery of Small-Molecule Inhibitors of Protein-Protein Interactions between HIV-1 Integrase and Cellular Cofactor LEDGF/p75. ChemMedChem 4: 1311–1316.
12. Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, et al. (2003) Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J Am Chem Soc 125: 3714–3715.
13. Boehr DD, Nussinov R, Wright PE, (2009) The role of dynamic conformational ensembles in biomolecular recognition. Nature Chem Biol 5: 789–796.
14. Bucher D, Grant BJ, McCammon JA, (2011) Induced fit or conformational selection? The role of the semi-closed state in the maltose binding protein. Biochemistry 50: 10530–10539.
15. Ma B, Kumar S, Tsai CJ, Nussinov R, (1999) Folding funnels and binding mechanisms. Protein Engineering 12: 713–720.
16. Tsai CJ, Ma B, Nussinov R, (1999) Folding and binding cascades: shifts in energy landscapes. Proc Nat Acad Sci U S A 96: 9970–9972.
17. Csermely P, Palotai R, Nussinov R, (2010) Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends Biochem Sci 35: 539–546.
18. Zhou HX, (2010) From induced fit to conformational selection: a continuum of binding mechanism controlled by the timescale of conformational transitions. Biophysical J 98: L15–17.
19. Wlodarski T, Zagrovic B, (2009) Conformational selection and induced fit mechanism underlie specificity in noncovalent interactions with ubiquitin. Proc Nat Acad Sci U S A 106: 19346–19351.
20. Eyrisch S, Helms V, (2007) Transient pockets on protein surfaces involved in protein-protein interaction. J Med Chem 50: 3457–3464.
21. Metz A, Pfleger C, Kopitz H, Pfeiffer-Marek S, Baringhaus KH, et al. (2012) Hot spots and transient pockets: Predicting the determinants of small-molecule binding to a protein-protein interface. J Chem Inf Model 52: 120–133.
22. Kokh DB, Richter S, Henrich S, Czodrowski P, Rippmann F, et al. (2013) TRAPP: A tool for analysis of transient binding pockets in proteins. J Chem Inf Model 53: 1235–1252.
23. Johnson DK, Karanicolas J, (2013) Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface. PLoS Comp Bio 9: e1002951.
24. Meireles L, Gur M, Bakan A, Bahar I, (2011) Pre-existing soft modes of motion uniquely defined by native contact topology facilitate ligand binding to proteins. Protein Science 20: 1645–1658.
25. Tobi D, Bahar I, (2005) Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state. Proc Nat Acad Sci USA 102: 18908–18913.
26. Yang L, Song G, Jernigan RL, (2007) How well can we understand large-scale protein motions using normal modes of elastic network models? Biophysical J 93: 920–929.
27. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235–242.
28. Lange OF, Lakomek NA, Fares C, Schroder GF, Walter KFA, et al. (2008) Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Science 320: 1471–1475.
29. DeLano WL, (2002) Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 12: 14–20.
30. Clackson T, Wells JA, (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267: 383–386.
31. Mattos C, Ringe D, (1996) Locating and characterizing binding sites on proteins. Nature Biotech 14: 595–599.
32. Ciulli A, Williams G, Smith AG, Blundell TL, Abell C, (2006) Probing hot spots at protein-ligand binding sites: A fragment-based approach using biophysical methods. J Med Chem 49: 4992–5000.
33. Winter A, Higueruelo AP, Marsh M, Sigurdardottir A, Pitt WR, et al. (2012) Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Quar Rev Biophysics 45: 383–426.
34. Hajduk PJ, Huth JR, Fesik SW, (2005) Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 48: 2518–2525.
35. Dennis S, Kortvelyesi T, Vajda S, (2002) Computational mapping identifies the binding sites of organic solvents on proteins. Proc Nat Acad Sci U S A 99: 4290–4295.
36. Silberstein M, Dennis S, Brown L, Kortvelyesi T, Clodfelter K, et al. (2003) Identification of substrate binding sites in enzymes by computational solvent mapping. J Mol Biol 332: 1095–1113.
37. Vajda S, Guarnieri F, (2006) Characterization of protein-ligand interaction sites using experimental and computational methods. Curr Opin Drug Disc Dev 9: 354–362.
38. Lavi A, Ngan CH, Movshovitz-Attias D, Bohnuud T, Yueh C, et al. (2013) Detection of peptide-binding sites on protein surfaces: the first step toward the modeling and targeting of peptide-mediated interactions. Proteins 81: 2096–2105.
39. Brenke R, Kozakov D, Chuang GY, Beglov D, Hall D, et al. (2009) Fragment-based identification of druggable ‘hot spots’ of proteins using Fourier domain correlation techniques. Bioinformatics 25: 621–627.
40. Ngan CH, Hall DR, Zerbe B, Grove LE, Kozakov D, et al. (2012) FTSite: high accuracy detection of ligand binding sites on unbound protein structures. Bioinformatics 28: 286–287.
41. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, et al. (2008) BAX activation is initiated at a novel interaction site. Nature 455: 1076–U1076.
42. Michelsen K, Jordan JB, Lewis J, Long AM, Yang E, et al. (2012) Ordering of the N-terminus of human MDM2 by small molecule inhibitors. J Am Chem Soc 134: 17059–17067.
43. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948–953.
44. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844–848.
45. Hocker HJ, Rambahal N, Gorfe AA, (2014) LIBSA–a method for the determination of ligand-binding preference to allosteric sites on receptor ensembles. J Chem Inf Model 54: 530–538.
46. Vertessy BG, Orosz F, (2011) From “fluctuation fit” to “conformational selection”: evolution, rediscovery, and integration of a concept. BioEssays 33: 30–34.
47. Gao M, Skolnick J, (2013) A comprehensive survey of small-molecule binding pockets in proteins. PLoS Comp Biol 9: e1003302.
48. Skolnick J, Gao M, (2013) Interplay of physics and evolution in the likely origin of protein biochemical function. Proc Nat Acad Sci U S A 110: 9344–9349.
49. Grove LE, Hall DR, Beglov D, Vajda S, Kozakov D, (2013) FTFlex: accounting for binding site flexibility to improve fragment-based identification of druggable hot spots. Bioinformatics 29: 1218–1219.
50. Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, et al. (2005) Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 350: 587–598.
51. Long JF, Tochio H, Wang P, Fan JS, Sala C, et al. (2003) Supramodular structure and synergistic target binding of the N-terminal tandem PDZ domains of PSD-95. J Mol Biol 327: 203–214.
52. Piserchio A, Salinas GD, Li T, Marshall J, Spaller MR, et al. (2004) Targeting specific PDZ domains of PSD-95: Structural basis for enhanced affinity and enzymatic stability of a cyclic peptide. Chem Biol 11: 469–473.
53. Charbonnier S, Nomine Y, Ramirez J, Luck K, Chapelle A, et al. (2011) The structural and dynamic response of MAGI-1 PDZ1 with noncanonical domain boundaries to the binding of human papillomavirus E6. J Mol Biol 406: 745–763.
54. Fromm SA, Truffault V, Kamenz J, Braun JE, Hoffmann NA, et al. (2012) The structural basis of Edc3- and Scd6-mediated activation of the Dcp1:Dcp2 mRNA decapping complex. EMBO Journal 31: 279–290.
55. Follis AV, Chipuk JE, Fisher JC, Yun MK, Grace CR, et al. (2013) PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nature Chem Biol 9: 163–168.
56. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, et al. (1997) Structure of Bcl-x(L)-Bak peptide complex: Recognition between regulators of apoptosis. Science 275: 983–986.
57. Kozakov D, Brenke R, Comeau SR, Vajda S, (2006) PIPER: An FFT-based protein docking program with pairwise potentials. Proteins 65: 392–406.